Combination therapy for high-risk multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma that came back or did not respond after initial treatment.
- You have measurable signs of myeloma in your blood or urine.
- You are generally in good physical condition (able to care for yourself).
- Your kidney, liver, and heart function are within acceptable limits.
- You have not had a blood clot or stroke before.
- You have not been treated with daratumumab before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of the drugs daratumumab, carfilzomib, lenalidomide, and dexamethasone given before and after a stem cell transplant for people with ultra high-risk multiple myeloma. The goal is to see if this regimen is safe and more effective than standard treatments.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This trial tests a new drug combined with other medicines for people with multiple myeloma, a related condition called AL amyloidosis, or high-risk smoldering multiple myeloma. It aims to see if the combination is safe and effective.
This trial tests a combination of three drugs (CM336, daratumumab, and lenalidomide) for people with newly diagnosed multiple myeloma who are not eligible for a stem cell transplant. The goal is to see if this combination is safe and effective in controlling the disease.
This trial tests whether a new drug called cevostamab, combined with two existing myeloma drugs (pomalidomide and dexamethasone), works better than standard treatment for people whose myeloma has returned or stopped responding to prior therapy. You would receive this combination to see if it helps control your disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.